Halozyme Therapeutics | HALO - Ordinary Share Capital


Halozyme Therapeutics reported $114.04M in Ordinary Share Capital for its fiscal quarter ending in June of 2026.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amarin USD 20.81M 13K Dec/2025
Amgen USD 541M 1000K Jun/2026
Baxter International USD 517M 549K Jun/2026
Cara Therapeutics USD 9.38M 2.01K Mar/2026
Cytokinetics USD 124.43M 2.17M Mar/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Eli Lilly USD 943.5M 3.33M Mar/2026
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Intrexon USD 0 0 Jun/2024
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
MannKind USD 309.91M 1M Jun/2026
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 29.47M 9.09M Mar/2026
Pfizer USD 5.7B 0 Jun/2026
Rigel Pharmaceuticals USD 17K 158K Jun/2024
United Therapeutics USD 42.68M 521K Jun/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024